Semin Respir Crit Care Med 2024; 45(01): 128-140
DOI: 10.1055/s-0043-1777267
Review Article

Pulmonary Aspergillosis in People with Cystic Fibrosis

C. Schwarz
1   HMU-Health and Medical University, Potsdam, Germany
2   Division Cystic Fibrosis, Clinic Westbrandenburg, Potsdam, Germany
,
P.N. Eschenhagen
1   HMU-Health and Medical University, Potsdam, Germany
2   Division Cystic Fibrosis, Clinic Westbrandenburg, Potsdam, Germany
,
J.G. Mainz
3   Department of Paediatric Pneumology, Allergology, Cystic Fibrosis Center, Klinikum Westbrandenburg, Brandenburg a. d. Havel, Germany
4   University Hospital of the Brandenburg Medical School, Brandenburg a. d. Havel, Germany
,
T. Schmidergall
1   HMU-Health and Medical University, Potsdam, Germany
2   Division Cystic Fibrosis, Clinic Westbrandenburg, Potsdam, Germany
,
H. Schuette
5   Pneumology and Respiratory Medicine, Ernst von Bergmann Klinikum, Potsdam, Germany
,
E. Romanowska
1   HMU-Health and Medical University, Potsdam, Germany
2   Division Cystic Fibrosis, Clinic Westbrandenburg, Potsdam, Germany
› Author Affiliations

Abstract

In the last decade, fungal respiratory diseases have been increasingly investigated for their impact on the clinical course of people with cystic fibrosis (CF), with a particular focus on infections caused by Aspergillus spp. The most common organisms from this genus detected from respiratory cultures are Aspergillus fumigatus and Aspergillus terreus, followed by Aspergillus flavus, Aspergillus niger, and Aspergillus nidulans. These species have been identified to be both chronic colonizers and sources of active infection and may negatively impact lung function in people with CF. This review article discusses definitions of aspergillosis, challenges in clinical practice, and current literature available for laboratory findings, clinical diagnosis, and treatment options for pulmonary diseases caused by Aspergillus spp. in people with CF.



Publication History

Article published online:
29 January 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Blomquist A, Inghammar M, Al Shakirchi M. et al. Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study. BMC Pulm Med 2022; 22 (01) 263
  • 2 Bercusson A, Jarvis G, Shah A. CF fungal disease in the age of CFTR modulators. Mycopathologia 2021; 186 (05) 655-664
  • 3 Schwarz C. Clinical relevance of fungi in cystic fibrosis. Semin Respir Crit Care Med 2023; 44 (02) 252-259
  • 4 Singh A, Ralhan A, Schwarz C, Hartl D, Hector A. Fungal pathogens in CF airways: leave or treat?. Mycopathologia 2018; 183 (01) 119-137
  • 5 Baxter CG, Dunn G, Jones AM. et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013; 132 (03) 560-566.e10
  • 6 Düesberg U, Wosniok J, Naehrlich L, Eschenhagen P, Schwarz C. Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function. Sci Rep 2020; 10 (01) 18999
  • 7 Li BCM, Huh SM, Prieto MD. et al. Biomarkers for the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2021; 9 (05) 1909-1930.e4
  • 8 Veit G, Avramescu RG, Chiang AN. et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 2016; 27 (03) 424-433
  • 9 Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J 2014; 44 (04) 1042-1054
  • 10 Earle K, Valero C, Conn DP. et al. Pathogenicity and virulence of Aspergillus fumigatus. . Virulence 2023; 14 (01) 2172264
  • 11 Saint-Criq V, Gray MA. Role of CFTR in epithelial physiology. Cell Mol Life Sci 2017; 74 (01) 93-115
  • 12 Durie PR, Kent G, Phillips MJ, Ackerley CA. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 2004; 164 (04) 1481-1493
  • 13 Rubin BK, Thornton DJ. Dropping acid: why is cystic fibrosis mucus abnormal?. Eur Respir J 2018; 52 (06) 1802057
  • 14 Turcios NL. Cystic fibrosis lung disease: an overview. Respir Care 2020; 65 (02) 233-251
  • 15 Burgel PR, Paugam A, Hubert D, Martin C. Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infect Drug Resist 2016; 9: 229-238
  • 16 Hong G, Alby K, Ng SCW. et al. The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis. J Cyst Fibros 2020; 19 (01) 125-130
  • 17 Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 2010; 9 (02) 110-116
  • 18 Güngör O, Tamay Z, Güler N, Erturan Z. Frequency of fungi in respiratory samples from Turkish cystic fibrosis patients. Mycoses 2013; 56 (02) 123-129
  • 19 Pihet M, Carrere J, Cimon B. et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis – a review. Med Mycol 2009; 47 (04) 387-397
  • 20 Inglis SK, Corboz MR, Ballard ST. Effect of anion secretion inhibitors on mucin content of airway submucosal gland ducts. Am J Physiol 1998; 274 (05) L762-L766
  • 21 Matsui H, Grubb BR, Tarran R. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95 (07) 1005-1015
  • 22 Åstrand AB, Hemmerling M, Root J. et al. Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition. Am J Physiol Lung Cell Mol Physiol 2015; 308 (01) L22-L32
  • 23 Goldberg JB, Pier GB. The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis. Trends Microbiol 2000; 8 (11) 514-520
  • 24 Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax 2016; 71 (03) 284-287
  • 25 Caverly LJ, LiPuma JJ. Good cop, bad cop: anaerobes in cystic fibrosis airways. Eur Respir J 2018; 52 (01) 1801146
  • 26 Gresnigt MS, Rekiki A, Rasid O. et al. Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the interleukin-1 receptor. Sci Rep 2016; 6: 26490
  • 27 Kang Y, Yu Y, Lu L. The role of pentraxin 3 in aspergillosis: reality and prospects. Mycobiology 2020; 48 (01) 1-8
  • 28 Garlanda C, Hirsch E, Bozza S. et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420 (6912): 182-186
  • 29 Chaudhary N, Datta K, Askin FB, Staab JF, Marr KA. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am J Respir Crit Care Med 2012; 185 (03) 301-310
  • 30 Law SM, Stanfield SJ, Hardisty GR, Dransfield I, Campbell CJ, Gray RD. Human cystic fibrosis monocyte derived macrophages display no defect in acidification of phagolysosomes when measured by optical nanosensors. J Cyst Fibros 2020; 19 (02) 203-210
  • 31 Di A, Brown ME, Deriy LV. et al. CFTR regulates phagosome acidification inmacrophages and alters bactericidal activity. Nat Cell Biol 2006; 8 (09) 933-944
  • 32 Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010; 123 (Pt 24): 4195-4200
  • 33 Gil ML, Peñalver MC, Lopez-Ribot JL, O'Connor JE, Martinez JP. Binding of extracellular matrix proteins to Aspergillus fumigatus conidia. Infect Immun 1996; 64 (12) 5239-5247
  • 34 Moretti S, Renga G, Oikonomou V. et al. A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. Nat Commun 2017; 8: 14017
  • 35 Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11 (04) 275-288
  • 36 Carvalho A, De Luca A, Bozza S. et al. TLR3 essentially promotes protective class I-restricted memory CD8+ T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood 2012; 119 (04) 967-977
  • 37 Carsin A, Romain T, Ranque S. et al. Aspergillus fumigatus in cystic fibrosis: an update on immune interactions and molecular diagnostics in allergic bronchopulmonary aspergillosis. Allergy 2017; 72 (11) 1632-1642
  • 38 Sales-Campos H, Tonani L, Cardoso CR, Kress MR. The immune interplay between the host and the pathogen in Aspergillus fumigatus lung infection. BioMed Res Int 2013; 2013: 693023
  • 39 Scheffold A, Schwarz C, Bacher P. Fungus-specific CD4 T cells as specific sensors for identification of pulmonary fungal infections. Mycopathologia 2018; 183 (01) 213-226
  • 40 Schwarz C, Eschenhagen P, Schmidt H. et al. Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis. J Clin Invest 2023; 133 (05) e161593
  • 41 Bacher P, Heinrich F, Stervbo U. et al. Regulatory T cell specificity directs tolerance versus allergy against aeroantigens in humans. Cell 2016; 167 (04) 1067-1078.e16
  • 42 O'Gorman CM. Airborne Aspergillus fumigatus conidia: a risk factor for aspergillosis. Fungal Biol Rev 2011; 25 (03) 151-157
  • 43 Latgé JP, Chamilos G. Aspergillus fumigatus and Aspergillosis in 2019. Clin Microbiol Rev 2019; 33 (01) e00140-e18
  • 44 Abad A, Fernández-Molina JV, Bikandi J. et al. What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis. Rev Iberoam Micol 2010; 27 (04) 155-182
  • 45 Perez-Cuesta U, Guruceaga X, Cendon-Sanchez S. et al. Nitrogen, iron and zinc acquisition: key nutrients to Aspergillus fumigatus virulence. J Fungi (Basel) 2021; 7 (07) 518
  • 46 Rokas A. Aspergillus. Curr Biol 2013; 23 (05) R187-R188
  • 47 Croft CA, Culibrk L, Moore MM, Tebbutt SJ. Interactions of Aspergillus fumigatus conidia with airway epithelial cells: a critical review. Front Microbiol 2016; 7: 472
  • 48 van de Veerdonk FL, Gresnigt MS, Romani L, Netea MG, Latgé JP. Aspergillus fumigatus morphology and dynamic host interactions. Nat Rev Microbiol 2017; 15 (11) 661-674
  • 49 Baltussen TJH, Zoll J, Verweij PE, Melchers WJG. Molecular mechanisms of conidial germination in Aspergillus spp. Microbiol Mol Biol Rev 2019; 84 (01) e00049-e19
  • 50 Bhabhra R, Askew DS. Thermotolerance and virulence of Aspergillus fumigatus: role of the fungal nucleolus. Med Mycol 2005; 43 (Suppl. 01) S87-S93
  • 51 Do JH, Yamaguchi R, Miyano S. Exploring temporal transcription regulation structure of Aspergillus fumigatus in heat shock by state space model. BMC Genomics 2009; 10: 306
  • 52 Valiante V, Macheleidt J, Föge M, Brakhage AA. The Aspergillus fumigatus cell wall integrity signaling pathway: drug target, compensatory pathways, and virulence. Front Microbiol 2015; 6: 325
  • 53 Chamilos G, Carvalho A. Aspergillus fumigatus DHN-melanin. Curr Top Microbiol Immunol 2020; 425: 17-28
  • 54 Shlezinger N, Irmer H, Dhingra S. et al. Sterilizing immunity in the lung relies on targeting fungal apoptosis-like programmed cell death. Science 2017; 357 (6355): 1037-1041
  • 55 Schwarz C, Vandeputte P, Rougeron A. et al; ECMM/ISHAM Working Group Fungal respiratory infections in Cystic Fibrosis (Fri-CF). Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. Med Mycol 2018; 56 (Suppl. 01) 42-59
  • 56 Schwarz C, Bouchara JP, Buzina W. et al. Organization of patient management and fungal epidemiology in cystic fibrosis. Mycopathologia 2018; 183 (01) 7-19
  • 57 Reece E, McClean S, Greally P, Renwick J. The prevalence of Aspergillus fumigatus in early cystic fibrosis disease is underestimated by culture-based diagnostic methods. J Microbiol Methods 2019; 164: 105683
  • 58 Williams C, Ranjendran R, Ramage G. Pathogenesis of fungal infections in cystic fibrosis. Curr Fungal Infect Rep 2016; 10 (04) 163-169
  • 59 Al Shakirchi M, Sorjonen K, Klingspor L, Bergman P, Hjelte L, de Monestrol I. The effects of Aspergillus fumigatus colonization on lung function in patients with cystic fibrosis. J Fungi (Basel) 2021; 7 (11) 944
  • 60 Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407 (6805): 762-764
  • 61 Seidler MJ, Salvenmoser S, Müller FM. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother 2008; 52 (11) 4130-4136
  • 62 Mowat E, Butcher J, Lang S, Williams C, Ramage G. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus . J Med Microbiol 2007; 56 (Pt 9): 1205-1212
  • 63 Beauvais A, Schmidt C, Guadagnini S. et al. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus . Cell Microbiol 2007; 9 (06) 1588-1600
  • 64 Jubin V, Ranque S, Stremler Le Bel N, Sarles J, Dubus JC. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010; 45 (08) 764-771
  • 65 Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens?. Int J Biochem Cell Biol 2014; 52: 161-173
  • 66 Paugam A, Baixench MT, Demazes-Dufeu N. et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010; 48 (Suppl. 01) S32-S36
  • 67 Hong G, Psoter KJ, Jennings MT. et al. Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis. J Cyst Fibros 2018; 17 (05) 624-630
  • 68 Cimon B, Carrère J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19 (01) 53-56
  • 69 Coron N, Pihet M, Fréalle E. et al. Toward the standardization of mycological examination of sputum samples in cystic fibrosis: results from a French multicenter prospective study. Mycopathologia 2018; 183 (01) 101-117
  • 70 Skov M, McKay K, Koch C, Cooper PJ. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med 2005; 99 (07) 887-893
  • 71 Saunders RV, Modha DE, Claydon A, Gaillard EA. Chronic Aspergillus fumigatus colonization of the pediatric cystic fibrosis airway is common and may be associated with a more rapid decline in lung function. Med Mycol 2016; 54 (05) 537-543
  • 72 Ramsey KA, Ranganathan S, Park J. et al; AREST CF. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Respir Crit Care Med 2014; 190 (10) 1111-1116
  • 73 Grehn C, Eschenhagen P, Temming S, Düesberg U, Neumann K, Schwarz C. Urban life as risk factor for aspergillosis. Front Cell Infect Microbiol 2020; 10: 601834
  • 74 Grehn C, Eschenhagen P, Temming S, Düesberg U, Neumann K, Schwarz C. Frequent pet contact as risk factor for allergic bronchopulmonary aspergillosis in cystic fibrosis. Front Cell Infect Microbiol 2021; 10: 601821
  • 75 Thronicke A, Heger N, Antweiler E. et al. Allergic bronchopulmonary aspergillosis is associated with pet ownership in cystic fibrosis. Pediatr Allergy Immunol 2016; 27 (06) 597-603
  • 76 Janahi IA, Rehman A, Al-Naimi AR. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ann Thorac Med 2017; 12 (02) 74-82
  • 77 Agarwal R, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Aggarwal AN. Allergic bronchopulmonary aspergillosis. Clin Chest Med 2022; 43 (01) 99-125
  • 78 Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy 2015; 45 (12) 1765-1778
  • 79 Asano K, Hebisawa A, Ishiguro T. et al; Japan ABPM Research Program. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol 2021; 147 (04) 1261-1268.e5
  • 80 Hong G, Desai S, Moss RB, Eschenhagen P, Quon BS, Schwarz C. Clinician variability in the diagnosis and treatment of Aspergillus fumigatus-related conditions in cystic fibrosis: an international survey. J Cyst Fibros 2022; 21 (01) 136-142
  • 81 Stevens DA, Moss RB, Kurup VP. et al; Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 (Suppl. 03) S225-S264 [ Erratum in: Clin Infect Dis. 2004 Jan 1;38(1):158. PMID: 12975753]
  • 82 Agarwal R, Chakrabarti A, Shah A. et al; ABPA Complicating Asthma ISHAM Working Group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43 (08) 850-873
  • 83 Eschenhagen P, Grehn C, Schwarz C. Prospective evaluation of Aspergillus fumigatus-specific IgG in patients with cystic fibrosis. Front Cell Infect Microbiol 2021; 10: 602836
  • 84 Renz DM, Scholz O, Böttcher J. et al. Comparison between magnetic resonance imaging and computed tomography of the lung in patients with cystic fibrosis with regard to clinical, laboratory, and pulmonary functional parameters. Invest Radiol 2015; 50 (10) 733-742
  • 85 Steels S, Proesmans M, Bossuyt X, Dupont L, Frans G. Laboratory biomarkers in the diagnosis and follow-up of treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Crit Rev Clin Lab Sci 2023; 60 (01) 1-24
  • 86 Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2016; 11 (11) CD002204
  • 87 Aaron SD, Vandemheen KL, Freitag A. et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012; 7 (04) e36077
  • 88 Koutsokera A, Corriveau S, Sykes J. et al. Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis. J Cyst Fibros 2020; 19 (01) 119-124
  • 89 Polverino E, Goeminne PC, McDonnell MJ. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50 (03) 1700629
  • 90 Thomson JM, Wesley A, Byrnes CA, Nixon GM. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41 (02) 164-170
  • 91 Cohen-Cymberknoh M, Blau H, Shoseyov D. et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros 2009; 8 (04) 253-257
  • 92 Arora S, Haghi M, Loo CY, Traini D, Young PM, Jain S. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection. Mol Pharm 2015; 12 (06) 2001-2009
  • 93 Proesmans M, Vermeulen F, Vreys M, De Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr 2010; 2010: 376287
  • 94 Moni SS, Al Basheer A. Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies. Saudi Pharm J 2022; 30 (12) 1736-1747
  • 95 Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130 (01) 222-226
  • 96 Chrdle A, Mustakim S, Bright-Thomas RJ, Baxter CG, Felton T, Denning DW. Aspergillus bronchitis without significant immunocompromise. Ann N Y Acad Sci 2012; 1272: 73-85
  • 97 Brandt C, Roehmel J, Rickerts V, Melichar V, Niemann N, Schwarz C. Aspergillus bronchitis in patients with cystic fibrosis. Mycopathologia 2018; 183 (01) 61-69
  • 98 Ullmann AJ, Aguado JM, Arikan-Akdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018; 24 (Suppl. 01) e1-e38
  • 99 Donnelly JP, Chen SC, Kauffman CA. et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71 (06) 1367-1376
  • 100 Alexander BD, Lamoth F, Heussel CP. et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC/MSGERC. Clin Infect Dis 2021; 72 (Suppl. 02) S79-S88
  • 101 Schwarz C, Brandt C, Whitaker P. et al. Invasive pulmonary fungal infections in cystic fibrosis. Mycopathologia 2018; 183 (01) 33-43
  • 102 Schwarz C, Hartl D, Eickmeier O. et al. Progress in definition, prevention and treatment of fungal infections in cystic fibrosis. Mycopathologia 2018; 183 (01) 21-32
  • 103 Mortensen KL, Jensen RH, Johansen HK. et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49 (06) 2243-2251
  • 104 Ruhnke M, Cornely OA, Schmidt-Hieber M. et al. Treatment of invasive fungal diseases in cancer patients - revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses 2020; 63 (07) 653-682
  • 105 Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49 (Suppl. 01) S90-S95
  • 106 Denning DW, Cadranel J, Beigelman-Aubry C. et al; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47 (01) 45-68
  • 107 Guo L, Wu X, Wu X. Aspergillus infection in chronic obstructive pulmonary diseases. Clin Respir J 2023; 17 (03) 129-138
  • 108 Logan M, McLoughlin R, Gibney RG. Aspergilloma complicating cystic fibrosis. AJR Am J Roentgenol 1993; 161 (03) 674-675
  • 109 Maguire CP, Hayes JP, Hayes M, Masterson J, FitzGerald MX. Three cases of pulmonary aspergilloma in adult patients with cystic fibrosis. Thorax 1995; 50 (07) 805-806
  • 110 Ryan PJ, Stableforth DE, Reynolds J, Muhdi KM. Treatment of pulmonary aspergilloma in cystic fibrosis by percutaneous instillation of amphotericin B via indwelling catheter. Thorax 1995; 50 (07) 809-810
  • 111 Chow L, Brown NE, Kunimoto D. An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis. Clin Infect Dis 2002; 35 (09) e106-e110
  • 112 Bouchara JP, Cremet L, Delhaès L. et al. Broncho-pulmonary infections and cystic fibrosis. In: Rémic - Référentiel en microbiologie médicale, 76 ème édition 20182022. Société Française de Microbiologie; 20182022: pp. 21365–27320. (in French)
  • 113 The UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group. Laboratory standards for processing microbiological samples from people with cystic fibrosis. First edition; 2010. Accessed October 30, 2023 at: https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/Laboratorystandards.pdf
  • 114 Hong G, Miller HB, Allgood S, Lee R, Lechtzin N, Zhang SX. Use of selective fungal culture media increases rates of detection of fungi in the respiratory tract of cystic fibrosis patients. J Clin Microbiol 2017; 55 (04) 1122-1130
  • 115 Parent-Michaud M, Dufresne PJ, Fournier E. et al. Prevalence and mechanisms of azole resistance in clinical isolates of Aspergillus section Fumigati species in a Canadian tertiary care centre, 2000 to 2013. J Antimicrob Chemother 2020; 75 (04) 849-858
  • 116 Masoud-Landgraf L, Badura A, Eber E, Feierl G, Marth E, Buzina W. Modified culture method detects a high diversity of fungal species in cystic fibrosis patients. Med Mycol 2014; 52 (02) 179-186
  • 117 Stokell JR, Khan A, Steck TR. Mechanical homogenization increases bacterial homogeneity in sputum. J Clin Microbiol 2014; 52 (07) 2340-2345